Actions and Detail Panel
Public Lecture: Large scale bioinformatics data integration and data mining...
Tue, July 18, 2017, 2:00 PM – 3:00 PM Malaysia Time Malaysia (Kuala Lumpur) Time
Title: Large scale bioinformatics data integration and data mining of resources for improved target identification and validation in various therapeutic areas
Genomics Technology Infrastructure, European Bioinformatics Institute
Open Targets is a public-private partnership made up of four global leading institutions in the fields of pharmaceuticals, bioinformatics and genomics, namely GSK, EMBL-EBI, the Wellcome Trust Sanger Institute, and Biogen. We combine large-scale genomic experiments to identify and validate the causal links between targets, pathways and diseases. We have recently developed the Target Validation platform, a web application for data integration and visualisation, which supports both target- and disease-centric workflows.
Our platform enables biomedical researchers to discover and prioritise biological targets for new therapies. We derive evidence of association between a target and a disease from multiple public domain resources, including germline and somatic genetics. An association score, which takes into account the observed frequency, the experiment confidence, and the likely strength of the effect of the target on the disease was also provided. By drawing on expertise in product and platform development including product testing, UX design and site development, we have created this comprehensive and robust data integration for access and visualisation. In addition, programmatic retrieval of data via RESTful endpoints and/or using our API clients, in R and Python. The Target Validation Platform is aimed at users from both academia and industry, whether you want to browse a target on a gene by gene (or disease by disease) basis, carry out more complex queries using the API, or download all evidence and association objects for downstream analyses.
For more information about the talk, please visit our website.